These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
88 related articles for article (PubMed ID: 20373885)
21. The effect of disease-modifying antirheumatic drugs on retinal function in the electrophysiological ex vivo model of the isolated perfused vertebrate retina. Ranjbar M; Schneider T; Brand C; Grisanti S; Lüke J; Lüke M Ophthalmic Res; 2015; 53(3):136-40. PubMed ID: 25720991 [TBL] [Abstract][Full Text] [Related]
22. The effects of the phosphodiesterase type V inhibitor sildenafil on human and bovine retinal function in vitro. Lüke M; Szurman P; Schneider T; Lüke C Graefes Arch Clin Exp Ophthalmol; 2007 Aug; 245(8):1211-5. PubMed ID: 17345091 [TBL] [Abstract][Full Text] [Related]
23. Prolonged blockade of VEGF receptors does not damage retinal photoreceptors or ganglion cells. Miki A; Miki K; Ueno S; Wersinger DM; Berlinicke C; Shaw GC; Usui S; Wang Y; Zack DJ; Campochiaro PA J Cell Physiol; 2010 Jul; 224(1):262-72. PubMed ID: 20232317 [TBL] [Abstract][Full Text] [Related]
24. Investigating retinal toxicity of tempol in a model of isolated and perfused bovine retina. Januschowski K; Mueller S; Dollinger R; Schnichels S; Hofmann J; Spitzer MS; Bartz-Schmidt KU; Szurman P; Thaler S Graefes Arch Clin Exp Ophthalmol; 2014 Jun; 252(6):935-41. PubMed ID: 24789463 [TBL] [Abstract][Full Text] [Related]
25. Glutamate and hypoxia as a stress model for the isolated perfused vertebrate retina. Januschowski K; Müller S; Krupp C; Spitzer MS; Hurst J; Schultheiss M; Bartz-Schmidt KU; Szurman P; Schnichels S J Vis Exp; 2015 Mar; (97):. PubMed ID: 25868118 [TBL] [Abstract][Full Text] [Related]
26. Comparison of bevacizumab, ranibizumab, and pegaptanib in vitro: efficiency and possible additional pathways. Klettner A; Roider J Invest Ophthalmol Vis Sci; 2008 Oct; 49(10):4523-7. PubMed ID: 18441313 [TBL] [Abstract][Full Text] [Related]
27. Investigating retinal toxicity of a lutein-based dye in a model of isolated and perfused bovine retina. Mueller S; Krupp C; Schnichels S; Hofmann J; Spitzer M; Bartz-Schmidt KU; Szurman P; Januschowski K Graefes Arch Clin Exp Ophthalmol; 2019 May; 257(5):961-966. PubMed ID: 30788607 [TBL] [Abstract][Full Text] [Related]
29. Pegaptanib 1-year systemic safety results from a safety-pharmacokinetic trial in patients with neovascular age-related macular degeneration. ; Apte RS; Modi M; Masonson H; Patel M; Whitfield L; Adamis AP Ophthalmology; 2007 Sep; 114(9):1702-12. PubMed ID: 17509689 [TBL] [Abstract][Full Text] [Related]
30. Anti-VEGF aptamer (pegaptanib) therapy for ocular vascular diseases. Ng EW; Adamis AP Ann N Y Acad Sci; 2006 Oct; 1082():151-71. PubMed ID: 17145936 [TBL] [Abstract][Full Text] [Related]
31. The effects of the intraocular dye brilliant blue G (BBG) mixed with varying concentrations of glucose on retinal function in an isolated perfused vertebrate retina. Januschowski K; Mueller S; Spitzer MS; Lueke M; Bartz-Schmidt KU; Szurman P Graefes Arch Clin Exp Ophthalmol; 2011 Apr; 249(4):483-9. PubMed ID: 20853117 [TBL] [Abstract][Full Text] [Related]
32. Multifocal electroretinography in patients with exudative amd and intravitreal treatment with pegaptanib sodium. Lipski A; Bornfeld N; Jurklies B Retina; 2007 Sep; 27(7):864-72. PubMed ID: 17891010 [TBL] [Abstract][Full Text] [Related]
33. Effects of daunorubicin and CD95L on retinal function in superfused vertebrate retina. Hueber A; Lüke M; Esser PJ; Kirchhof B; Sickel W; Lüke C J Ocul Pharmacol Ther; 2005 Apr; 21(2):133-8. PubMed ID: 15857279 [TBL] [Abstract][Full Text] [Related]
34. Pegaptanib sodium for neovascular age-related macular degeneration: two-year safety results of the two prospective, multicenter, controlled clinical trials. ; D'Amico DJ; Masonson HN; Patel M; Adamis AP; Cunningham ET; Guyer DR; Katz B Ophthalmology; 2006 Jun; 113(6):992-1001.e6. PubMed ID: 16647134 [TBL] [Abstract][Full Text] [Related]
35. Safety of intravitreal bevacizumab in the developing rabbit retina. Zayit-Soudry S; Zemel E; Barak A; Perlman I; Loewenstein A Retina; 2011 Oct; 31(9):1885-95. PubMed ID: 21799464 [TBL] [Abstract][Full Text] [Related]
36. Effects of anti-VEGF treatment on the recovery of the developing retina following oxygen-induced retinopathy. Tokunaga CC; Mitton KP; Dailey W; Massoll C; Roumayah K; Guzman E; Tarabishy N; Cheng M; Drenser KA Invest Ophthalmol Vis Sci; 2014 Mar; 55(3):1884-92. PubMed ID: 24550366 [TBL] [Abstract][Full Text] [Related]
37. Simultaneous but not prior inhibition of VEGF165 enhances the efficacy of photodynamic therapy in multiple models of ocular neovascularization. Ju M; Mailhos C; Bradley J; Dowie T; Ganley M; Cook G; Calias P; Lange N; Adamis AP; Shima DT; Robinson GS Invest Ophthalmol Vis Sci; 2008 Feb; 49(2):662-70. PubMed ID: 18235012 [TBL] [Abstract][Full Text] [Related]
38. Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease. Ng EW; Shima DT; Calias P; Cunningham ET; Guyer DR; Adamis AP Nat Rev Drug Discov; 2006 Feb; 5(2):123-32. PubMed ID: 16518379 [TBL] [Abstract][Full Text] [Related]
39. [Effect of VEGF165 and the VEGF aptamer pegaptanib (Macugen) on the protein composition of tight junctions in microvascular endothelial cells of the retina]. Deissler HL; Lang GE Klin Monbl Augenheilkd; 2008 Oct; 225(10):863-7. PubMed ID: 18951306 [TBL] [Abstract][Full Text] [Related]
40. Effects of phosphodiesterase type 5 inhibitor sildenafil on retinal function in isolated superfused retina. Lüke M; Lüke C; Hescheler J; Schneider T; Sickel W J Ocul Pharmacol Ther; 2005 Aug; 21(4):305-14. PubMed ID: 16117694 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]